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a b s t r a c t
Advances in molecular immunology have unveiled some of the complexity of the mechanisms regulating
cellular immune responses and led to the successful targeting of immune checkpoints in attempts to enhance antitumor T cell responses. Surgery, chemotherapy, and radiation therapy have been the mainstay
of treatment in urologic malignancies. Immune checkpoint molecules such as cytotoxic T-lymphocyte associated protein-4, programmed cell death protein-1, and programmed death-ligand 1 have been shown
to play central roles in evading cancer immunity. Thus these molecules have been targeted by inhibitors
for the management of cancers forming the basis of immunotherapy. Immunotherapy is now among
the ﬁrst line therapeutic options for metastatic renal cell carcinomas. In advanced bladder cancer, immunotherapy is the standard of care in the second line and the ﬁrst line for cisplatin ineligible patients.
There continues to be ongoing research to identify the role if any of immunotherapy in testicular, prostatic, and penile cancers. The ideal biomarker for response to immunotherapy is still elusive. Although
programmed death-ligand 1 immunohistochemical testing has been widely used across the globe as a
biomarker for immunotherapy, companion diagnostic tests have inherent issues with testing and reporting and cannot have universal applicability. Additional biomarkers including, tumor mutational burden,
deﬁcient mismatch repair, high microsatellite instability, and immune gene expression proﬁling are being
evaluated in various clinical trials. This review appraises the data of immunotherapy in the management
of urologic malignancies.
© 2020 Elsevier Inc. All rights reserved.

Introduction
Traditionally systemic chemotherapy has been the mainstay of
treatment for metastatic malignancies. However, such treatment
often has limited eﬃcacy and like most therapies associated
toxicities. Although the neoplastic cells are often chemosensitive
at the outset with a rapid reduction in the tumor mass, malignant
clone(s) may become refractory to the treatment and lead to
disease recurrence. Thus, the need to develop and deploy novel
therapeutics, and now for nearly two decades there has been
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increased interest in immunotherapy, speciﬁcally checkpoint
inhibitors [1].
Urologic malignancies are growths of abnormal cells that form
in the organs of the urinary system in both men and women, and
in the male genital organs including the testis, prostate, penis, and
the glands and ducts associated with these organs. Per GLOBOCAN 2018 data, prostatic malignancies are the third most common
cancer worldwide accounting for 1,276,106 cases detected annually
with 360,0 0 0 deaths. Annually, 550,0 0 0 cases of bladder cancer,
40 0,0 0 0 cases of renal cell carcinoma (RCC), 70,0 0 0 cases of testicular malignancies, and 35,0 0 0 penile cancers are reported; with
20 0,0 0 0 deaths from bladder cancer, 170,0 0 0 from RCC 9,0 0 0 from
testicular malignancies and 15,0 0 0 from penile cancers [2].
Until recently, surgery, chemotherapy, hormonal therapy, and
radiation therapy were the mainstay of treatment in these malignancies. However, recent advances in genomics, proteomics,
and pathway-based analyses have catalyzed and inﬂuenced the
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landscape of cancer research, fueling the development of novel
therapeutics, and deepening our understanding of immunotherapy.
As early as the 1990s, Leach et al demonstrated enhancement of
antitumor immunity by cytotoxic T-lymphocyte associated protein4 (CTLA-4) blockade [3]. And in 2003 Phan et al reported on the
eﬃcacy of cytotoxic T lymphocyte-associated antigen 4 blockade
in patients with metastatic melanoma [REF above].
Cancer immunity
The immune system has 2 lines of defense: innate immunity
and adaptive immunity. The components of innate immunity include phagocytes (neutrophils, macrophages, dendritic cells, and
natural killer [NK] cells), cytokines, and complements. This effectively serves as the ﬁrst line of defense. T- and B-lymphocytes constitute the principal components of the adaptive or acquired immune system [4,5]. In the context of a malignancy, tumor antigens
are presented by the dendritic cells in association with the major
histocompatibility complex (MHC) molecules and are recognized
by the T-cell receptors (TCR). Thus, dendritic cells act as a bridge
between innate and adaptive immunity. The T-cells mount an immune response against cancer in that it is speciﬁc (against the tumor antigens), has a memory (accelerated secondary response at
recurrence), and adaptive (caters to the tumor heterogeneity) [6,7].
Immune checkpoints
Activation of the immune system is closely regulated to avoid
autoimmunity. The activation of T-lymphocytes requires 2 signals:
the ﬁrst signal (signal 1) is received upon presentation by antigen presenting cells (APCs) of the MHC bound processed antigens
and polypeptide chain to the TCR [8]. The second signal for activation requires co-stimulation via binding of the molecules B7-1
and B7-2 expressed on APCs to their CD28 ligand on T-cells [9].
This process of T-cell activation and suppression is regulated by
various cytokines [10], and by so-called immune checkpoints. Immune checkpoint receptors or molecules are membrane molecules
on T-lymphocytes that recognize the ligands on APCs and tumor
cells and can play a positive or negative role in the process of
the T-lymphocyte activation [11]. Programmed cell death protein
(PD-1) and CTLA-4 are the most well studied immune checkpoint
molecules expressed on T-lymphocytes [12,13].
CTLA-4-mediated immune checkpoint
CTLA-4 expression and function are intrinsically linked to Tcell activation. Most of the CTLA-4-based T-cell regulation occurs
in the peritumoral lymph nodes. It is immediately up-regulated
following TCR engagement and competes with the costimulatory
molecule CD28 for its ligands, B7-1 (CD80) and B7-2 (CD86) expressed on the APCs [14]. It should be noted that CD80 and CD86
are antigens that are not generally expressed on nonhematological
cancer cells but are expressed on APCs, including dendritic cells
and monocytes. Since both B7-1 and B7-2 provide positive costimulatory signals through CD28, their binding with CTLA-4 effectively inhibits signal 1 between the TCR and MHC. Thus, it leads
to the suppression of T-cell response [14]. Studies by Allison et
al showed that administration of monoclonal antibodies against
CTLA-4 induced tumor rejection and also led to immunity against
secondary exposure to tumor antigens [15]. In 2011, the FDA approved theCTLA-4–blocking antibody, ipilimumab, as the ﬁrst immune checkpoint inhibitor for the therapy of cancer in metastatic
melanoma [16]. As mentioned, the maximum CTLA-4 interaction
occurs in the secondary lymphoid organs rather than the tumor
microenvironment, and this has been a major hurdle in ﬁnding
tumor-speciﬁc biomarkers for anti-CTLA-4 response (Fig. 1a).

PD-1/PD-L-mediated immune checkpoint
Another “classical” immune checkpoint molecule, PD-1 interacts with its ligands PD-L-1 and PD-L2. These are constitutively
expressed at moderate levels in several nonlymphoid tissues, such
as heart, lungs, and placenta (responsible for playing a critical role
in fetal-maternal tolerance) and are also induced by inﬂammatory
signals [17]. In the setting of immune activation and inﬂammation,
PD-1 expression is induced on the CD4+ and CD8+T-cells, B-cells,
NK cells, NKT cells, macrophages, and some dendritic cells. The interaction of PD-L1 with PD-1 triggers PD-1 phosphorylation and recruitment of the SHP2 phosphatase. PD-1-associated SHP2 dephosphorylates CD28 and TCR signaling to inhibit the T-cell response
restricting over reactive T-cell and hence autoimmunity [18]. Binding of PD-L1 expressed on the tumor cells to PD-1 leads to inhibition of the signal 1 between the TCR and MHC. It thus inhibits
T cell activation. Unlike, CTLA-4, the interaction between PD-1 and
PD-L1 occurs on the tumor cells itself (Fig. 1b) [17,18].
Other immune checkpoint molecules
Further studies into the T-cell costimulatory molecules have
revealed several proteins belonging to multiple structurally deﬁned superfamilies. Among these molecules are LAG3, TIM3, TIGIT,
VISTA, and ICOS from the immunoglobulin superfamily and OX40,
GITR, 4-1BB, CD40, and CD27 from the tumor necrosis factor receptor superfamily etc. However, we lack the fundamental knowledge regarding the biological roles of these molecules. There are
many additional costimulatory molecules of uncertain therapeutic value, including newly identiﬁed B7 ligand family members
[19–24]. The various immune checkpoint molecules, their ligands,
expression and biological functions are described (Table 1).
PD-L1 assay by IHC
Antibody clones
Different PD-L1/PD-1 antibodies have been approved for use
as biomarkers for immune checkpoint blockade in various malignancies, including the genitourinary malignancies as illustrated
in Table 2. The clones approved and tested commonly include
22C3, 28-8, SP142, SP263, and E1L3N [25–28]. These clones have
been validated and compared in numerous studies, where Fleiss
kappa and intraclass correlation coeﬃcient analyses showed excellent agreement and reliability among all antibodies [29–31]. The
main difference between these antibodies lies primarily in their
different scoring algorithms.
Positive PD-L1 staining/expression is deﬁned as complete
and/or partial, circumferential or linear plasma membrane staining at any intensity that can be differentiated from the background
and diffuse cytoplasmic staining. Certain speciﬁc terminologies are
universally used during the evaluation and reporting of PD-L1,
which are as follows: TC: entire tumor cell; IC: entire immune cell;
PTC: PD-L1-positive tumor cell; PIC: PD-L1-positive immune cell
(Figs. 2 and 3). The scoring for various clones in urologic malignancies is described below.
SP142: PIC/(TC+PTC)
22C3: Combined Positive Score (CPS) = ((PTC+PIC)/(TC+PTC))
x100
SP263: The tumor cell score (TC-Score) = PIC/(IC+PIC) or
PTC/(PTC+TC)
28-8: Tumor Proportion Score (TPS) = Percentage of viable tumor cells showing partial or complete membrane staining.
Points to be considered while evaluating biomarkers of immune
checkpoint blockade [32]
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Fig. 1. (A)The role of CTLA-4 and its inhibitors in cancer immunity is illustrated. (B) The role of PD-1/PD-L1 and their inhibitors in cancer immunity is illustrated.

1. It is advised to use freshly cut tissue samples, as stored
slides may yield improper results. Sample ﬁxation in 10%
neutral buffered formalin is preferred. There appears to be
no effect of delayed ﬁxation on PD-L1 immunohistochemistry (IHC) [33]. However, these ﬁndings need to be further
substantiated. Decalciﬁcation performed with Ethylene diamine tetra acetic acid (EDTA) or acid decalciﬁer lowers the
proportion and intensity of the stained cells with PD-L1 using the 22C3 clone, but not in the E1L3N clone [33].
2. Most of the immune checkpoint inhibitors are approved for
use in invasive tumors, thus it is mandatory to have part
of the invasive component of the tumor in the section on
which biomarkers are being evaluated. If initially only a superﬁcial biopsy was provided, it is advised to request a fresh
biopsy with adequate invasive component for evaluation.

3. At least 100 viable tumor cells are required for evaluation.
Avoid areas with extensive necrosis and hemorrhage.
4. Tonsil is used as a positive control as the crypt epithelium shows strong PD-L1 staining. Additionally, the immune cells including macrophages, lymphocytes, and dendritic cells within the tonsil exhibit an intermediate to
strong cytoplasmic or membranous staining.
Role of immune checkpoint inhibitors in urothelial carcinoma
of the bladder
Bladder cancer is the 11th most common cancer worldwide accounting for 549,0 0 0 new cases annually. There is a male predilection and it is the 14th leading cause of cancer mortality per
GLOBOCAN 2018 data [2]. Urothelial carcinoma of the bladder ac-

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on February 22, 2021.
For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

370

R. Sardana, S.K. Mishra and S.R. Williamson et al. / Seminars in Oncology 47 (2020) 367–379

Table 1
Immune checkpoint inhibitory molecules and their functions.
Checkpoint molecules

Ligand(s)

Expression pattern

Cellular mechanism

Biological function

CTLA4 [15]

• B7-1 (CD80)
• B7-2 (CD86)

• T-cells particularly T-regulatory
cells

• Competitive inhibition of
CD28 co-stimulation

• Inhibition of T-cell

PD-1 [18]

• PD-L1
• PD-L2

•
•
•
•
•
•

• Attenuate proximal T-cell
receptor signaling

• Inhibition of T-cell

LAG3 [22]

• MHC II
• LSECtin

• T-cells
• Natural killer cells
• T-regulatory cells

• Mechanism unknown

• Negative regulator of T-cell
expansion
• Control T-cell homeostasis,
• Dendritic cell activation

TIM3 [23]

• Galectin-9
• HMGB1
• CEACAM-1

•
•
•
•
•
•

Th1 CD4
Tc1 CD8
T-regulatory cells
Dendritic cells
Natural killer cells
Monocytes

• Negative regulation of
proximal T-cell receptor
components

• Negative regulation of type 1
immunity

TIGIT [24]

• PVR (CD155)
• PVRL2 (CD112)

•
•
•
•

T-cells
T-regulatory cells
TFH
NK cells

• Competitive inhibition of
DNAM1(CD226)

• Negative regulation of T-cell
activity

T-cells
Natural killer cells
NKT- cells
B-cells
Macrophages,
Subsets of dendritic cells

CEACAM-1 = carcinoembryonic antigen-related cell adhesion molecules-1; CTLA-4 = cytotoxic T Lymphocytes Antigen-4; HMGB1 = high mobility group protein B1;
LAG3 = lymphocyte-activation gene 3; LSECTIN = liver and lymph node sinusoidal endothelial cell C-type lectin; MHC = major histocompatibility complex; PD-1 = programmed
death receptor 1; PD-L1 = programmed death receptor ligand 1; PVR = poliovirus receptor; PVRL2 = poliovirus receptor-related 2; Th = T-helper cell; Tc = type 1 CD8+T-cells;
TIGIT, T-cell immunoreceptor with Ig and ITIM domains;TIM3 = T-cell immunoglobulin mucin-3.
Table 2
Different clones of PD-1/PD-L1 used in urothelial carcinoma.
Antibody clone

Staining platform

Staining characteristics

Drug for which the clone is
approved

22C3 [25]

DAKO

• Homogenous membranous
tumor cell staining
• Mostly weak staining
intensity

Pembrolizumab [anti-PD-1]

• CPS ≥10

28-8 [26]

DAKO

• Homogenous membranous
tumor cell staining
• Strong staining intensity

Nivolumab [anti-PD-1]

• TPS >1%

SP142 [27]

Ventana

• Dot like staining pattern
• Low tumor cell staining

Atezolizumab [anti-PD-L-1]

• >5% tumor cells are
positive

• All immune cells (including
granulocytes) apart from
the plasma cells are
included in the scoring

SP263 [28]

Ventana

• Homogenous cytoplasmic
Durvalumab [anti-PD-L-1]
and membranous tumor cell
staining
• Mostly strong staining
intensity

• ≥25% tumor immune cell
area and/or 25% of tumor
cells

• Immune cell positivity is
scored according to the
area occupied by all
immune cells.
• Assay is positive only if
one or both cut-offs are
exceeded.
• All immune cells (including
granulocytes) apart from
the plasma cells are
included in the scoring.

E1L3N [29]

Cell Signaling
Technologies

No data sheet available

Positivity criteria

Remarks
• CPS includes immune cells
and tumor cells
• Plasma cells and
neutrophils need to be
excluded from scoring

• Used as ≥25% in studies

CPS = combined positive score; TPS = tumor proportion score.

counts for ≈95% of bladder tumors with ≈70% of patients presenting with nonmuscle disease [34]. These patients are treated with
localized therapies including transurethral resection of the bladder
tumor and adjuvant intravesical agents like Bacillus Calmette–
Guérin or intravesical chemotherapy. For patients with recurrent
Bacillus Calmette–Guérin-unresponsive high-risk carcinoma in
situ with or without papillary tumors who are either unwilling/ineligible for cystectomy, pembrolizumab may be a treatment

option based on high rates of complete (38.8%) and durable responses (median 14 months) [35,36]. The mainstay of treatment in
muscle invasive bladder cancer (MIBC) is radical cystectomy. Based
on preference, patients may be treated with neoadjuvant or adjuvant cisplatin-based chemotherapy. Neoadjuvant cisplatin-based
chemotherapy regimens are associated with pathological complete
responses (pCR) of ≈30% and attainment of pCR is associated with
improved survival [37–39]. The role of immunotherapy in MIBC in
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Fig. 2. Diagrammatic representations of certain speciﬁc terminologies used during
the evaluation and reporting of PD-L1 (TC: entire tumor cell; IC: entire immune
cell; PTC: PD-L1-positive tumor cell; PIC: PD-L1-positive immune cell).

the neoadjuvant or adjuvant setting is an area of intense research
[40]. The PURE-01 study included 114 patients with a new diagnosis of MIBC and any histology, including 19 patients with predominant variant histology (VH) deﬁned as involving >50% of the
tumor specimens, who were treated with 3 cycles of neoadjuvant
pembrolizumab prior to radical cystectomy. The primary endpoint
was pathological complete response (pT0) in the intention to treat
population. The pT0 rate in the ITT population was 37% with
responses seen even in the VH. Six of the 7 patients with predominant VH presented with squamous cell carcinoma and 6 of the 7
had downstaging to pT1 with one pT0; 2 of 3 lymphoepitheliomalike variants had a pT0 response. None of the remaining 9
predominant VHs had a response. TMB and CPS were predictors of
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pT0 irrespective of histology. Pembrolizumab was associated with
few immune-related adverse events and did not delay planned
surgery, nor increase postsurgical complications [41,42].
In the phase II ABACUS study including 95 patients with MIBC,
2 cycles of neoadjuvant atezolizumab led to pathological complete response in 31% of patients. Baseline biomarkers showed
pre-existing activated T-cell expression correlated with outcome
whereas unlike ﬁndings in the metastatic setting, TMB was not
predictive of outcome [43–44]. Studies have shown the feasibility
of combining gemcitabine and cisplatin chemotherapy with pembrolizumab or nivolumab in the neoadjuvant setting with pCR rates
of 44% and 49%, respectively [45–46].
Cisplatin-based chemotherapy is the treatment of choice in patients with metastatic urothelial carcinoma of the bladder. Overall
response rates (ORRs) range from 60% to 70%, overall survival (OS)
from 14 to 15 months, and 5-year survival from 13% to 15% [47]. In
patients who relapse after platinum-based chemotherapy, the ORR
ranges from 5% to 29% with a median OS of 6.9 months based
on clinical trials of second-line chemotherapy with paclitaxel and
vinﬂunine [48]. The clinical trials involving immune checkpoint inhibitors in the management of urothelial carcinoma of the bladder
are summarized in Table 3 [49–57].
For practical purposes, combination cisplatin-based chemotherapy remains the standard of care in the treatment of metastatic
urothelial carcinoma. This includes patients with urothelial carcinoma of the bladder, ureter, renal pelvis, and urethra. In patients
eligible for cisplatin, atezolizumab with or without chemotherapy was studied in the IMvigor 130 trial in frontline metastatic
urothelial carcinoma. Although there was a statistically signiﬁcant
improvement in the progression-free survival (PFS) in the experimental arm, the OS data are still immature [49]. Based on these
results, at the present time combination immunotherapy plus
chemotherapy should not be considered as the standard of care
in frontline metastatic urothelial carcinoma. Cisplatin ineligibility

Fig. 3. (A) Metastatic clear cell renal cell carcinoma (hematoxylin and eosin, original magniﬁcation x200). (B) Strong and linear incomplete to circumferential PD-L1 staining in 70% of the metastatic clear cell renal cell carcinoma cells (SP-263 PD-L1 immunohistochemistry, original magniﬁcation x400). (C) Metastatic urothelial carcinoma
(Hematoxylin and eosin, original magniﬁcation x200). (D) Strong and circumferential PD-L1 staining in 90% of the metastatic urothelial carcinoma cells (SP-263 PD-L1 immunohistochemistry, original magniﬁcation x400).
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Table 3
Clinical trials involving the immune checkpoint inhibitors in urothelial carcinomas.
•
•
•
•

ICI
Design
Study
Eligibility Criteria
Phase of study
Reference

•
•
•
•

Pembrolizumab
KEYNOTE 052
Phase 2
O’ Donell et al
[38]

• First-line UCa
• Ineligible for
platinum-based
chemotherapy

• CPS assessed by IHC
22C3 pharmDx assay
[DAKO]

• Single arm: Pembrolizumab 200
mg q3 weeks for 2 years

• ORR 29%; CPS ≥10;
47%; CPS <10; 20%
• 30% had CPS ≥10

• Grade ≥3 AEs, 21%
• Fatigue and pruritus

•
•
•
•

Pembrolizumab
Keynote 045
Phase 3
Bellmunt et al
[39]

• UCa that recurred
or progressed after
platinum-based
chemotherapy

• CPS assessed by IHC
22C3 pharmDx assay
[DAKO]

• Pembrolizumab 200 mg q 3 weeks
X 24 months vs
• Investigator’s choice paclitaxel,
docetaxel, or vinﬂunine

• OS: 10.1 vs 7.2 months
(HR 0.7 95% CI
0.57–0.85 P = 0.0 0 03
• OS CPS ≥10,8 vs 5.2
months
• Beneﬁt irrespective of
CPS

• Grade 3 AE, 17 vs 50%

•
•
•
•

ATEZOLIZUMAB
IMvigor 210
Phase 2
Balar et al [40]

• First-line UCa
• Ineligible for
platinum-based
chemotherapy

• IC assessed by SP142
assay [Ventana]

• Atezolizumab 1,200 mg q3 weeks
until progression

• ORR 23%
• Responses irrespective
of IC
• High tumor mutational
load predictive of
better response and
survival

• Grade 3 AE, 16%
• Fatigue, pruritus, and
diarrhea

•
•
•
•

ATEZOLIZUMAB
IMvigor 130
Phase 3
Grande et al
[41]

• First-line advanced/
metastatic UCa

• IC as assessed by SP142
assay, [Ventana]

• PFS:
• Arm A – Atezolizumab q3
- Arm A 8.2 months
weeks + gemcitabine + carboplatin
or cisplatin
- Arm C 6.3 months
• Arm B – Atezolizumabq3 weeks
(HR, 0.82 [95% CI:
• Arm C –
0.70, 0.96;
Placebo + gemcitabine + carboplatin
P = 0.007)
or cisplatin
• ORR:
- Arm A 47%
- Arm B 23%
- Arm C 44%
• OS: Data immature

• Rx withdrawal due to
AE:
- Arm A 34%
- Arm B 6%
- Arm C 34%

•
•
•
•

ATEZOLIZUMAB
IMvigor211
Phase 3
Powles et al
[42]

• UCa that recurred
or progressed after
platinum-based
chemotherapy

• IC as assessed by SP142
assay [Ventana]

• Atezolizumab1200 mg q 3 weeks
vs
• Investigator’s choice of paclitaxel,
docetaxel, or vinﬂunine until
progression

• OS: PD-L1 IC2/3 11.1 vs
10.6 months; NS
• ORR: PD-L1 IC 2/3 23%
vs 22%
• DOR longer with
atezolizumab

• Grade 3/4 AE, 20% vs
43%
• Discontinuation rate
due to AE, 7% vs 18%

•
•
•
•

NIVOLUMAB
CheckMate 275
Phase 2
Sharma et al
[43]

• UCa that recurred
or progressed after
platinum-based
chemotherapy

• Tumor cell staining
≥1% or ≥5% assessed
by IHC 28-8 pharmDx
assay[DAKO]

• Nivolumab 3 mg/kg q2 weeks
until disease progression

• ORR 19.6%
• No difference in ORR
between PD-L1 IHC
≥5% or <5%

• Grade 3 AEs, 18%
• Fatigue and diarrhea

•
•
•
•
•

NIVOLUMAB+
IPILIMUMAB
CheckMate 032
Phase 2
Sharma et al
[44]

• UCa that recurred
or progressed after
platinum-based
chemotherapy

• Tumor cell staining
≥1% assessed by IHC
28-8 pharmDx assay
[DAKO]

• NIVO3
• NIVO3+IPI1 NIVO1+IPI3
• Expansion cohorts

• ORR
- NIVO3 = 25.6%
NIVO3+IPI1 = 26.9%
- NIVO1+IPI3 = 38%
• ORR highest for
PD-L1≥1%

• Grade 3/4 AEs:
- NIVO3 = 26.9%
NIVO3+IPI1 = 30.8%
- NIVO1+IPI3 = 39%

• AVELUMAB
• JAVELIN solid
tumor
• Phase 1
• Patel et al [45]

• UCa that recurred
or progressed after
platinum-based
chemotherapy

• Tumor cell staining
≥5% assessed by
IHC73-10 pharmDx
assay[DAKO]

• Avelumab 10 mg/kg q2 weeks
until progression

• ORR 17%; PD-L1+ 24%;
PD-L1– 14%

• Grade 3 AEs, 8%
• Fatigue

•
•
•
•

• UCa that recurred
or progressed after
platinum-based
chemotherapy

• SP263 assay [Ventana]

• Durvalumab 10 mg/kg q2 weeks
until progression

• ORR 18%; PD-L1 high
28%; PD-L1 low 5%

• Grade 3 AEs, 7%

DURVALUMAB
Study 1108
Phase 1/2
Powles et al
[46]

Companion Diagnostic Kit

Study arm

Outcomes

Toxicities

AE = adverse events; CI = conﬁdence interval; CPS = combined proportion score deﬁned as number of PD-L1 staining cells (tumor cells, immune cells) divided by the total number of viable tumor cells, multiplied by 100; DOR = duration of response; HR = hazard ratio; IC = immune cells (PD-L1 expression on tumor-inﬁltrating immune
cells);IC0 (PD-L1 expression on <1% of IC), IC1 (PD-L1 expression on ≥1% and <5% of IC), or IC2/3 (PD-L1 expression on ≥5% of IC); ICI = immune checkpoint inhibitor;
IHC = immunohistochemistry; OR = overall response rate; OS = overall survival; PD-L1, programmed death ligand 1; PD-L1+ (positive), ≥5% tumor cells with any intensity
PD-L1 expression in plasma membrane in; PD-L1– (negative),<5% tumor cells with any intensity of PD-L1 expression in plasma membrane; PD-L1 “high,” ≥25% of either
TCs or immune cells staining for PD-L1; PD-L1 “low or negative,” <25% of both TCs and immune cells staining for PD-L1;Platinum-ineligible (ECOG PS 2, CrCl ≥30 to ˂60
mL/min, grade ≥2 neuropathy/hearing loss, NYHA Class III heart failure);UCa = urothelial carcinoma.
Treatment Regimens: NIVO 3 = nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1 = nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses
followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI3 = nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab
monotherapy 3 mg/kg every 2 weeks.
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is deﬁned as an Eastern Cooperative Oncology Group performance
status greater than 2; a creatinine clearance less than 60 mL/min;
neuropathy/hearing loss grade 2 or higher; and New York Heart
Association heart failure grade 3 or higher [50,51]. Patients ineligible for cisplatin can be considered for frontline immunotherapy.
Pembrolizumab (Keynote 052) and atezolizumab (IMvigor 210)
have shown ORRs of 23%–29% and a manageable toxicity proﬁle
in such patients. They have been approved by the FDA for this
indication based on superior overall response rates in comparison
to historical ORRs of 10% [50,51]. In the second line, although the
FDA has approved all 5 immune checkpoint inhibitors, the data
is strongest for pembrolizumab (Keynote 045), which showed a
statistically signiﬁcant improvement in survival compared to standard chemotherapy [52]. Atezolizumab did not show any survival
beneﬁt although it was well tolerated and the duration of response
was longer [53]. In an analysis of 120 patients with metastatic
urothelial carcinoma who received single-agent PD-1/PD-L1 inhibition, 28 of whom had mixed histology, pure versus mixed
urothelial histology was not predictive of a differential response
(hazard ratio [HR] 1.52, 95% conﬁdence interval [CI] 0.59–3.98, P=
0.39) suggesting that immunotherapy can be used in metastatic
urothelial carcinoma with pure or mixed histology [58].
Role of immune checkpoint inhibitors in RCC
Renal tumors account for about 403,0 0 0 new cases each year
and are the 15th most common cancers in the world [2]. Clear
cell carcinoma is the most common pathological subtype and
accounts for 70% of all RCCs. Nonclear cell carcinomas include
mainly papillary and chromophobe RCCs. Approximately 2%–3% of
all RCCs are hereditary. Several tumor suppressor genes involved in
the development of RCC including PBRM1, BAP1 (BRCA1-associated
protein), and SETD2, are located in the short arm of chromosome
3 where the VHL gene is located [59]. Studies have shown RCC
to be an immunogenic tumor [60]; however, tumor induced immunosuppression is frequent in these patients. This is mediated
by multiple mechanisms among which regulatory T lymphocytes
and myeloid-derived suppressor cells have been most widely
studied. CD4+CD25+Foxp3+regulatory T-cells are responsible for
maintaining immune homeostasis. A subpopulation of these cells
is expanded in the blood and tumor of patients with RCCs. Their
expansion correlates with a poor prognosis [61]. These cells cause
immunosuppression by producing the IL-10 and transforming
growth factor (TGF-β ) cytokines which inhibit dendritic cells,
ultimately leading to suppression of effector T-lymphocytes [62].
Studies in patients with RCC have also shown that CD4+T-cells
tend to express a naïve/resting phenotype [63]. Based on the above
knowledge, trials were initially designed to combat the suppression imposed by regulatory T-cell. PD-L1 expression is associated
with a poor prognosis in RCC presumably because of its immunosuppressive function. Interleukin-2 immunotherapy has been
shown to induce long lasting complete remissions, albeit in only
5%–7% of patients with advanced RCC [64]. It has been postulated
that anti PD-1 therapy will restore antitumor immunity and improve survival and this encouraged research into immunotherapy
targeting the PD-1– PD-L1 pathway to reinvigorate the tumor speciﬁc T-cell mediated immunity in RCC. One of the ﬁrst trials was
a phase II study of single agent CTLA-4 inhibitor, ipilimumab [65].
Based on results from the Checkmate 025 trial which evaluated
nivolumab in patients with advanced RCC refractory to inhibitors
of vascular endothelial growth factor (VEGF) pathway, nivolumab
became the ﬁrst immunotherapy to be approved for this indication
[66]. Given that both the VEGF and PD-L1 pathways are important
in the pathogenesis of RCC, it followed that concurrent inhibition
of VEGF signaling might enhance the eﬃcacy of immunotherapy
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in the front-line treatment of patients with metastatic RCC. Results
from studies combining this approach support this hypothesis and
these are summarized in Table 4 [66,68–71]. With a plethora of
new drugs approved in the front line, there is no clear indication
as to which regimen to choose. Based on the available data, the
National Comprehensive Cancer Network (NCCN) kidney cancer
panel has listed nivolumab + ipilimumab (CheckMate 214) and
axitinib + pembrolizumab (Keynote 426) as category 1 treatment
options for ﬁrst-line treatment of intermediate- and poor-risk
metastatic RCC. Axitinib + avelumab (JAVELIN Renal 101) is also included but not as a preferred option. For the favorable risk subset,
the NCCN panel recommends axitinib + pembrolizumab (Keynote
426) as one of the preferred options along with single agent antiVEGF tyrosine kinase inhibitors (TKIs). Nivolumab + ipilimumab
(CheckMate 214) and axitinib + avelumab (JAVELIN Renal 101)
are other therapeutic options. For patients with progression on
ﬁrst-line TKIs, nivolumab (CheckMate 025) is the category 1 recommendation. Based on data in frontline, nivolumab + ipilimumab
may also be considered as a preferred option although there are no
data for this combination in second line. Axitinib + pembrolizumab
and axitinib + avelumab are other options [67]. The recommendations made above are based on clinical trials in tumors with clear
cell histology. Most studies have excluded patients with nonclear
cell RCC. The NCCN panel recommends anti-VEGF TKIs as the
preferred option in this subset of patients [67]. Of special mention,
the combination of bevacizumab + atezolizumab (IM motion 151)
showed a PFS beneﬁt in the front line treatment of metastatic
clear cell and sarcomatoid RCC and can be considered in these
subsets of patients [71].
Role of immune checkpoint inhibitors in prostate cancer
Traditionally, androgen deprivation therapy (ADT) is the cornerstone of management of metastatic prostate cancer (PC). It
has been observed that ADT sensitizes the neoplastic cells to the
patient’s cell mediated immunity. Thus, combination of ADT with
immunotherapy is being explored in many clinical trials [72].
To date, immune checkpoint inhibitors have demonstrated only
very marginal beneﬁt in PC, particularly in metastatic castrate
resistant. This is possibly due to dysfunctional cell-mediated immunity (defective functioning of circulating T-cells and NK cells)
and an immunosuppressive tumor microenvironment (TME) with
a preponderance of immunosuppressive regulatory T-cells and
myeloid derived suppressor cells in the TME [73,74]. A few studies
have indicated that the presence of increased tumor inﬁltrating
(TILs) CD8+T-cells is associated with a poor prognosis [75–77] and
some have suggested that TILs in PC may be dysfunctional or
may have undergone anergy, exhaustion, or senescence, leading
to suppressed T-cell functioning even after the administration of
immune checkpoint inhibitors [26,78]. In 2010, the FDA approved
the ﬁrst dendritic cell-based vaccine (sipuleucel-T) as the only
immunotherapeutic option for asymptomatic mCRPC. There are
50 ongoing clinical trials involving PD-1/PD-L1 inhibitors and 19
trials with CTLA-4 inhibitors, either as single agents or as part of
combination therapy in patients with metastatic prostate cancer
[72]. In one that administered a combination a PC vaccine, GVAX,
and ipilimumab to men with mCRPC, Prostate speciﬁc antigen
(PSA) responses were seen in a quarter of the patients [79].
A combination of chemotherapy with immunotherapy has also
been explored, the concept being immunologic cell death during
chemotherapy releases neoantigens and damage associated molecular patterns potentiating local immune responses [80]. However,
2 phase 3 trials of the anti CTLA-4 antibody ipilimumab failed to
show an OS beneﬁt in patients with mCRPC whose tumors were
either chemotherapy-naive or had progressed on chemotherapy;
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Table 4
Clinical trials involving the immune checkpoint inhibitors in the renal cell carcinoma.
•
•
•
•

ICI
Study
Phase of study
Reference

Companion diagnostic kit

•
•
•
•

NIVOLUMAB + IPILIMUMAB
CheckMate 214
Phase 3
Motzer et al [53]

Tumor cell staining ≥1% vs
<1% and ≥5% vs <5% by IHC
28-8 pharmDx assay
[DAKO]

-

NIVOLUMAB
CheckMate 025
Phase 3
Motzer et al [55]

Tumor cell staining ≥1% vs
<1% and ≥5% vs <5% by IHC
28-8 pharmDx assay
[DAKO]

-

PEMBROLIZUMAB
Keynote 426
Phase 3
Rini et al [57]

•
•
•
•

•
•
•
•

Eligibility and study arms

• NIVO3+IPI1 vs
• Sunitinib in ﬁrst-line in
mCCRCC

Results

Toxicities

• OS:median not reached vs
26 months (HR 0.63; P
<0.001)
- Poor and intermediate
risk:
- 30 months OS 60 vs
47% (HR 0.66, 95% CI
0.54–0.80)
• ORR 42% vs 27%
• Good risk
- No difference in
outcome
- Beneﬁt irrespective of
PD-L1 status

Grade 3/4 AEs
• 46% vs 63%

Advanced CCRCC> progression on
ﬁrst-line anti angiogenic therapy:
• Nivolumab vs
• Everolimus

• Median OS: 25 months vs
19.6 months (HR 0.73, 95%
CI, 0.57–0.93; P = 0.002)
• ORR: (25% vs 5%, OR, 5.98;
95% CI, 3.68–9.72; P
<0.001)
• Beneﬁt irrespective of
PD-L1 expression

Grade 3/4 AEs
• 19% vs 37%

CPS assessed by IHC 22C3
pharm Dx assay
[DAKO]

First-line mCCRCC:
• Pembrolizumab + Axitinib vs
• Sunitinib

• OS at 12 months: 90% vs
78% (HR 0.53, 95% CI,
0.38–0.74; P <0.0 0 01)
• Median PFS: 15 months vs
11 months (HR 0.69, 95%
CI, 0.57–0.84; P <0.001)
• ORR 59% vs 36%, (P
<0.001)
• Beneﬁt seen irrespective of
PD-L1 expression

Grade 3 AEs
• 76% vs 71%

AVELUMAB
JAVELIN Renal 101
Phase 3
Motzer et al [58]

≥1% of immune cells staining
positive for PD-L1 by SP263
assay
[Ventana]

First-line mCCRCC:
• Avelumab + axitinib vs
• Sunitinib

• Median PFS in
PD-L1 + tumors: 13.8 vs 7.2
m (HR, 0.61, 95% CI,
0.47–0.79, P <0.001);
• Median PFS: improved in
ITT population
• Median OS: not
signiﬁcantly different
• ORR: 55% vs 25%

Grade 3/4 AEs
• 71% in each arm

ATEZOLIZUMAB
IMmotion 151
Phase 3
Rini et al [59]

<1% vs ≥1% of
tumor-inﬁltrating immune cells
expressing PD-L1 by SP142
assay
[Ventana]

First-line mCCRCC, or sarcomatoid
RCC
• Atezolizumab + Bevacizumab
vs
• Sunitinib

• Median PFS in
PD-L1 + tumors: 11.2 m vs
7.7 m (HR, 0·74, 95% CI
0·57–0·96, P = 0·0217)
• Median OS: not
signiﬁcantly different

Grade 3/4 AEs:
• 40% vs 54%

AE = adverse events; CCRCC = clear cell renal cell carcinoma; CI = conﬁdence interval; CPS = combined positive score; HR = hazard ratio; ICI = immune checkpoint inhibitor;
IHC = immunohistochemistry; ITT = intention to treat; OR = odds ratio; mCCRCC = metastatic clear cell renal cell carcinoma; ORR = overall response rate; OS = overall survival;
PD-L1 = programmed death ligand 1; PFS = progression-free survival; RCC = renal cell carcinoma.
Treatment Regimen: NIVO3+IPI1, nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks.

with only a slight improvement in PFS and a modest biochemical
response, neither signiﬁcant [81,82]. A combination of ipilimumab
and nivolumab reported responses in a quarter of patients with
asymptomatic mCRPC whose tumors had progressed after secondgeneration hormonal therapy and were chemotherapy-naive.
In patients whose tumors had been exposed to ataxane-based
chemotherapy, the ORR was 10% [83]. In a phase 1 trial in patients
with mCRPC, the ORR with pembrolizumab was 17% and 34%
of patients had stable disease [84]. Two retrospective analyses
have demonstrated beneﬁt from ICIs in PC harboring a germline
or somatic mismatch repair deﬁciency (dMMR) or microsatellite
instability high (MSI-H) genetic signature. In one study conducted
at the Memorial Sloan Kettering Cancer Center, dMMR/high mi-

crosatellite instability (MSI-H) was detected in 3.1% of metastatic
CRPC. Eleven patients were treated with anti-PD-1/PD-L1 therapy,
and 6 (54.5%) of these patients had greater than 50% reduction in
PSA levels with 4 additionally having radiographic responses. Five
(45.5%) patients overall were continuing to respond at 89 weeks
[85]. In a smaller study, PC with dMMR was demonstrated to be
particularly sensitive to both hormonal therapy (PFS 67 months
to initial ADT) and anecdotal responses to pembrolizumab with
a PFS of 9 months and PSA responses in 2 out of 4 patients [86].
Finally, pembrolizumab has demonstrated a durable response in a
treatment refractory PC with high mutational burden due to DNA
polymerase epsilon (POLE) mutation, even though the patient’s
tumor was shown to be microsatellite stable. This provides some
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support for the concept for POLE mutations as a biomarker for
response to immunotherapy, although the magnitude of the beneﬁt and the frequency with which it might be observed has not
been deﬁned and is not expected to be high [87]. To summarize,
the beneﬁt of immune checkpoint inhibitors in metastatic PC has
been very minimal unlike that observed in urothelial carcinoma
and RCC. This is an area of active and ongoing research.
Role of immune checkpoint inhibitors in testicular tumors
The testes are immunologically privileged sites. Germ cell
tumors (GCT) account for majority of testicular tumors and
are subdivided into seminoma and nonseminomatous subtypes.
The primary therapeutic modality is orchiectomy followed by
platinum-based chemotherapy. Cierna et al have conﬁrmed a lack
of PD-1 expression in testicular GCT, along with higher levels of
PD-L1 on the surface of neoplastic cells, compared to the adjacent
uninvolved testis [88]. Chovanec et al have demonstrated that
patients whose GCTs have higher levels of PD-L1 expression on
the TILs have better PFS and OS [89]. In another study, seminomas
had low expression of PD-L1 on tumor cells, with higher expression on TILs, whereas teratomas had high expression of PD-L1
on tumor cells, but low expression on TILs. Among the GCTs,
seminomas have the highest frequency of PD-L1 positive TILs
(95.9% of cases), followed by embryonal carcinomas (91.0%), yolk
sac tumors (60%), choriocarcinomas (54.5%), and teratomas (35.7%)
[90]. One of the other factors that modify the PD-L1 expression
is the wingless-related integration site signaling pathway, which
results in a low number of TILs and reduces the effectiveness of
immune checkpoint inhibitors. The wingless-related integration
site signaling pathway is commonly activated in nonseminomatous
GCTs compared to seminomas [91–93]. Immune checkpoint inhibitors have rarely been used in platinum refractory GCTs. Tumor
regression was reported in one case of metastatic embryonal carcinoma treated with nivolumab [94]. Zschäbitz et al published their
experience on 7 platinum-refractory nonseminomatous germ cell
tumors that were treated with nivolumab or pembrolizumab. In
3 of the 7 patients, the tumors displayed some amount of tumor
regression. However, there was no association between the PD-L1
staining and the response to therapy [95]. A phase 2 clinical trial
in relapsed GCTs reported a clinical response in 2 of 12 patient
treated with pembrolizumab [96].
Role of immune checkpoint inhibitors in penile carcinoma
Penile squamous cell carcinomas are rare malignancies and
the prognosis with metastatic disease is dismal. Cisplatin- and
paclitaxel-based chemotherapy is the mainstay of treatment in
advanced penile squamous cell carcinomas. Newer therapeutic
modalities are an unmet need in this neoplasm. None of the
immune checkpoint inhibitors are currently approved in the
treatment of advanced penile squamous cell carcinomas. A few
studies have shown high expression of PD-L1 on tumor cells and
a correlation of this expression with nodal metastases and an
overall poor survival. In a retrospective analysis using an indigenously developed anti PD-L1 antibody (Clone 5H1), Udager et
al have demonstrated PD-L1 positivity (deﬁned as membranous
staining in ≥5% of tumor cells) in 62% of the primary tumors
[97]. PD-L1 expression was associated with higher regional nodal
involvement and reduced cancer speciﬁc survival. Interestingly
there was no signiﬁcant expression of PD-L1 on immune cells in
the tumor microenvironment. In another study using the rabbit
monoclonal anti-PD-L1 antibody, cell signaling, E1L3N, 40% of
penile squamous cell carcinomas expressed PD-L1 deﬁned by the
presence of any membranous positivity on tumor or immune cells
in one or more representative spots. As described in the previous
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study, PD-L1 expression correlated with higher tumor stage and
nodal involvement [98]. Per both the studies, immune checkpoint
inhibitors should be explored as a possible treatment option for
penile squamous cell carcinomas. Pembrolizumab is approved
across many solid malignancies with MSI-H. However, there is a
paucity of data on MSI in the penile squamous cell carcinomas.
By using tumor mutational burden as a surrogate marker for MSI
(MSI-H tumors have high mutational load), 6% of penile squamous
cell carcinomas were shown to harbor a mutational burden of
20/megabase or greater. In contrast to other neoplasms where high
mutational load is a marker of MSI-H status, in penile squamous
cell carcinomas this ﬁnding probably results from POLE mutations
rather than mismatch repair deﬁciency [99,100]. Although POLE
and DNA polymerase delta 1 (POLD) mutations have been shown
to be predictive of response to ICIs across varied cancer types
including bladder and prostatic cancers independent of MSI status,
it remains to be proven whether the same can be extrapolated to
penile squamous cell carcinomas [101].
Biomarkers to assess the eﬃcacy of immune checkpoint
inhibitors
PD-L1 expression
PD-L1 is expressed in 20%–30% cases of metastatic urothelial carcinoma [102]. In bladder cancer it is both a prognostic
(increased expression correlates with advanced stage and worse
outcomes) and predictive marker for response to anti-PD-1 and
-PD-L1 therapy [103]. The beneﬁts from the immune checkpoint
inhibitors occur irrespective of PD-L1 expression. Although most
trials have analyzed the data based on a prespeciﬁed cut-off for
PD-L1 on IHC, the results do not consistently show improved
responses with higher PD-L1 expression an observation that may
not be surprising given that PD-L1 assays are not uniform across
clinical trials – neither in the assays utilized nor in the scoring of
results. While pembrolizumab and nivolumab clinical trials have
used the DAKO assays, Ventana assays have been used with durvalumab and atezolizumab. In the pembrolizumab and nivolumab
trials PD-L1 tumor cell staining has been used, whereas the IM
vigor trial uses PD-L1 immune cell staining. The cut-offs for PD-L1
staining are also different (Tables 2–4). Intertrial variability in
IHC staining may be responsible for variability in the observed
responses with different immune checkpoint inhibitors. Other factors worth considering in using PD-L1 as a standalone biomarker
for response to immunotherapy is the intratumoral heterogeneity
in its expression and its dynamic nature in space and time during
the course of disease [103,104]. Taken together there is an unmet
need for an ideal biomarker that predicts response to the immune
checkpoint inhibitors.
Tumor mutational burden
Genome wide analysis has revealed certain tumor speciﬁc
features that could be used effectively as a biomarker to predict
response to therapy with an immune checkpoint inhibitor. Higher
frequency of gene mutations, denoted as tumor mutational burden
(TMB) is deﬁned as the total number of mutations per coding area
of a tumor genome and a higher number of mutations increase
the chances of generating neo-tumor-antigens recognized by the
host immune system as immunogenic neoantigens [105–107].
TMB is quantiﬁed as the number of coding somatic mutations per
megabase (MB) of DNA [106]. Tumors with high TMB have been
demonstrated to have a microenvironment rich in immune cells
and Th1-associated cytokines [108]. Recent data suggests immune
checkpoint inhibitors to be more active in tumors with high mutation rates. Emerging data from The Cancer Genome Atlas indicated
that urothelial cancers harbored the third highest mutation rate
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[109]. It has been reported that TMB is more helpful to predict the
therapeutic beneﬁt of immune checkpoint inhibitors than neoantigen load [110]. TMB assessed by the comprehensive genomic
proﬁling assay performed by Foundation Medicine was evaluated
as a biomarker of response to anti-PD-1/PD-L1 immunotherapy
in a large variety of tumors including urothelial, penile, and
prostate cancers as well as GCTs. There appeared to be a positive
correlation between the TMB and response rate (P <0.001) with a
correlation coeﬃcient of 0.74 (R2 = 0.5476) signifying that 55% of
the differences in the objective response rate across cancer types
may be explained by the TMB [106]. In the IMvigor210 trial, TMB
assessed by targeted genomic proﬁling of 315 cancer related genes
(Foundation Medicine) correlated with a longer OS and ORR with
atezolizumab independent of PD-L1 expression. Patients whose tumors had the highest mutation load (≥16/MB)) had a signiﬁcantly
longer survival compared with patients whose tumors had lower
mutational loads (<16/MB) [HR 0.37, (95% CI 0.21–0.64)] [51,111].
DNA mismatch repair and microsatellite instability
Mutations in the mismatch repair (MMR) genes result in formation of microsatellites. These are short, repetitive sequence of DNA,
where DNA polymerases are particularly known to be error prone
[112]. This leads to DNA damage by single base pair insertions
and deletions (indels). MMR proteins are responsible for nucleotide
base excision and repair. These proteins are coded by 4 MMR genes
namely, MLH1, MLH2, MLH6, and PMS2. A mutation in these genes
leads to deﬁciency in MMR. A MSI-H is a hallmark of deﬁcient
mismatch repair or dMMR. Defects in the DNA repair machinery
leads to a tremendous increase in rate of mutations [113]. In MSIH cancers the accumulation of errors in microsatellites results in
the so called “mutator phenotype,” an array of abnormal peptides
that might represent a pool of tumor speciﬁc antigens that render
MSI-H tumors inherently more detectable by the host immune system [114]. Put together these factors are predictive of a response to
the immune checkpoint blockade tumors that are MSI-H.
Urologic malignancies also display a deﬁcient MMR signature as
evidenced by their increased incidence in the patients with Lynch
syndrome (LS). Upper tract urothelial carcinoma is the third most
common malignancy in LS with an incidence of 1%–5% in this setting. In a study including 115 patients with upper tract urothelial carcinoma 13.9% met the criteria for possible LS and 5.2% had
conﬁrmed LS using the Amsterdam II and MSI-IHC criteria for LS.
[115] Epidemiologic data and molecular characterization suggest
urothelial carcinoma (1%–20%) and prostate cancer (2- to 5-fold
increase in incidence) as unrecognized components of Lynch syndrome [116]. Using the MSI-calling software, MANTIS, researchers
from Ohio State University, performed whole-exome sequencing on
11,139 tumor-normal pairs across 39 cancer types. Based on their
data, MSI-H was detected in 0.49% of the bladder carcinomas, 1.47%
of clear cell RCC, 0.6% of prostatic adenocarcinoma, and none of the
testicular tumors [117]. These numbers are small in comparison to
other cancers such as colonic adenocarcinoma where 19% tumors
are MSI-H. Nevertheless, this small subset of patients could very
well be the ones which are most responsive to the immune checkpoint inhibitors. Indeed Le et al demonstrated durable responses
with pembrolizumab in metastatic cancers with dMMR across a
variety of solid malignancies [118,119].
The Cancer Genome Atlas subtypes of the urothelial carcinoma
Based on the gene expression proﬁling, urothelial carcinomas
are classiﬁed into basal and luminal subtypes. Basal type tumor
cells have higher PD-L1 expression on the tumor cells and immune
cells [109]. The Cancer Genome Atlas subtypes have been associated with prognostic differences in the survival and responses to

immunotherapy. In the IMvigor 210 trial, the luminal cluster II subtype had a statistically signiﬁcant higher response rate compared
to luminal cluster I, basal cluster I, and basal cluster II subtypes
[51,120]. In the CheckMate 275 trial with nivolumab; however, improved responses were seen in basal I subtype followed by luminal
II subtypes [54]. Thus, there is a variation in responses between
the cluster subtypes across the clinical trials.
Immune gene expression proﬁling
Tumor immunity results from a complex interplay between tumor cells and immune cells in the tumor microenvironment. A
comprehensive immune gene expression proﬁling of these cells
along with the chemokine and cytokine milieu may truly represent the ongoing interactions resulting in tumor immunity. In
the IMvigor 210 trial in metastatic urothelial carcinoma, a higher
CD8+T effector signature (PD-L1 positivity on immune cells by
IHC was associated with expression of genes in a CD8+T effector set) correlated with higher complete response rates to atezolizumab. CXCL-9 (P= 0.0057) and CXCL-10 (P= 0.0079) expression, (chemokines representative of the T effector signature) had a
higher response to immunotherapy [121]. While in the Checkmate
275 study that examined the activity of nivolumab in metastatic
urothelial carcinoma, a 25-gene interferon-gamma (IFN-γ ) signature derived from the pretreatment biopsies found a higher objective response rate to nivolumab in tumors with higher values in
the IFN-γ gene signature than in those with low values on the IFNγ expression score [54]. While IFN-γ is known to have favorable
effects on antitumor immunity, persistent signaling has been associated with adaptive resistance to checkpoint therapy. One of the
most important IFN-γ mediated effects is the increased expression
of PD-L1 and PD-L2 [121–123]. Prolonged exposure of cancer cells
to IFN-γ signaling leads to expression of a number of ligands for T
cell inhibition, which in turn leads to resistance to immune checkpoint inhibitors independent of the PD-1/PD-L1-pathway [124].
TGF-β signaling in the tumor stroma creates an immunosuppressive phenotype and promotes angiogenesis and metastases. Based
on data from the IMvigor210 study, Mariathasan et al showed that
increased TGF-β signature - TGF-β ligand, TGFB1, and a TGF-β
receptor, TGFBR2 - in ﬁbroblasts within the peritumoral stroma
was associated with a lack of response and poorer survival to atezolizumab especially in patients where CD8+T-cells were excluded
from the tumor parenchyma [125].
Long noncoding RNA
Long noncoding RNAs (lncRNAs) are molecules more than 200
nucleotides in length that do not have the ability to translate into
protein [126]. They are transcribed by RNA polymerase II and share
a structure similar to mRNA but lack an open reading coding frame
[127]. The best documented mechanism by which lncRNAs contribute to tumor immune evasion include the crumpling of the
antigen presentation through upregulation of PD-L1 expression and
attenuation of T-cell activities [128]. LNMAT1, a long noncoding
RNA was found to be over expressed in UC of bladder with lymphnodal metastasis [129].
POLE and POLD mutations
POLE and POLD are essential for proofreading and ﬁdelity in
DNA replication. They have mutational frequencies of 2.79% and
1.37% respectively across a variety of cancers including urothelial
and prostate cancer. Their germline or somatic mutations can lead
to a hypermutated phenotype with high TMB and serve as negative prognostic markers. Mutations in these genes are predictive of
survival beneﬁt from ICI therapy, (OS 34 m vs 18 m, P= 0.0038)

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on February 22, 2021.
For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

R. Sardana, S.K. Mishra and S.R. Williamson et al. / Seminars in Oncology 47 (2020) 367–379

although much less so when adjusted for MSI status and cancer
type (P= 0.047). No signiﬁcant differences in OS were observed
between patients with MSI-H and those patients with POLE/POLD1
mutations who were non-MSI-H [101].
In summary, immune checkpoint inhibitors are gaining
widespread usage in ﬁrst and second-line therapy regimens.
Studies that have examined the tumor microenvironment, TMB,
MSI status, and expression of immune checkpoints and their
ligands have increased our knowledge but it is clear we are still
very far from a full understanding of the factors that mediate
sensitivity or resistance to immunotherapy.
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